Liankang Biotechnology Group (00690-HK) announced that on January 17, 2020, Watshengyuan, a direct wholly-owned subsidiary of the Company, was the subscriber and China China Construction Bank The Shenzhen branch concluded the first subscription agreement and the second subscription agreement. According to this, the subscribers separately subscribed for “Qianyuan-Shunxin” (the first phase wealth management product in 2020) with a principal amount of RMB 5 million, with an expected annualized yield of 3.70%; and the subscription of “Qianyuan-Shunxin” (second phase wealth management product in 2020) for RMB 25 million. The products are expected to have an annualized yield of 3.80%. The products are all expected to have an annualized yield of 3.80%.China Construction BankWealth management products of the Shenzhen branch.

The company subscribes for treasury management purposes, and the subscription will be disbursed from the Group's internal resources. Given that wealth management products are less risky and more stable than other non-bank wealth management products, the company believes that the subscription will enable the group to make maximum use of its available capital in order to obtain satisfactory returns without adversely affecting the group's working capital and business operations.